Welcome to factory-direct-buy
Chongqing Saipu Nasi Technology Co., Ltd
Chongqing Saipu Nasi Technology Co., Ltd
Sign in or Join Free Now!

Manufacturer Video

Contact Us

Street Address
North New District
Country/Region
China (Mainland)/Chongqing
Telephone

86-023-13048470428

Raw Material CAS 1029877-94-8 Syr-472 Powder for Treating Type 2 Diabetes
Raw Material CAS 1029877-94-8 Syr-472 Powder for Treating Type 2 Diabetes
  • >= 1  Gram US $1.000
Supply Ability:
1000000 Gram/Grams per Week
Port:
Guangdong /China
Email:
Quantity:
Gram
  • Product Detils
  • Company Profile
Quick Details
Place of Origin:
China (Mainland)
Brand Name:
CQSP
Model Number:
1029877-94-8
Packaging & Delivery
25kg/barrel or as your inquiry
Product Description

Raw Material CAS 1029877-94-8 Syr-472 Powder for Treating Type 2 Diabetes

Basic Info.


Product name SYR-472

CAS NO 1029877-94-8

MF C18H20FN5O2.C4H6O4

Appearance White powder

Purity 99%

Certification ISO9001

Brand Name CQSP STEROID

Delivery time 4~6 working days once against of the payment

Port HONGKONG/SHENZHEN/SHANGHAI/NANJING

Express delivery EMS, DHL, TNT, FedEx, UPS

Payment Terms T/T, Western Union, Money Gram

Minimum order 10g

Supply Ability 1000kg/month

Storage Shading, confined preservation

Packaging 10g/100g/1000g/foil bag  According to request.

Product  Categories Trelagliptin;Inhibitors

Usage a novel once-weekly oral DPP-4 inhibitor for type 2 diabetes

Synonyms SYR-472;Trelagliptin;(succinate);SYR-472 succinate;

Trelagliptin Succinate (SYR-472);SYR 111472 succinate;Trelagliptin succinat

Reference FOB Price:$1/g


Trade Mark:CQSP


Shipping: DHL, EMS, FedEx, UPS

Shelf life:2 years

More details pls contact:Whatapp:86 13048470428  

 Skype/E-mail : summer at chembj.com


Product description:

 

SYR-472 is a novel once-weekly oral DPP-4 inhibitor for type 2 diabetes, which could be a treatment option when clinicians seek to improve medication adherence by reducing the number of required administrations.

 

In study, The incidence of treatment-emergent adverse events in each SYR-472 group was similar to that in the placebo group. The most common adverse event was nasopharyngitis in all groups. No episodes of hypoglycaemia defined by investigator occurred with any treatment during the study. Once-weekly SYR-472 treatment produced clinically and statistically significant improvements in glycaemic control in patients with type 2 diabetes. It was well tolerated and might be a new treatment option for patients with this disease.


The quality control process :

 

1)Purchasing

Thorough market research, understand the price of raw materials and performance.To the procurement source to understand fully, and fully guarantee the quality of the procurement of raw materials.

 

2) Inspection

Four steps: sampling, sample pretreatment, measuring and data processing.

 

3) Producing

a) Each operator must do self-inspection of producs and make the corresponding inspection records.

b) Full-time inspectors through check the operator self-inspection, and review and sign in the corresponding record. Full-time inspection is responsible for inspection of finished product, and make the finished product incoming inspection records.

 

4) Before selling

Test result can be provided before selling.

Third-party detection institution is allowed if you are not satisfied with test results.

 


 Hot selling pharmaceutical raw materials:


Folic acid CAS: 59-30-3

Ketoconazole CAS: 65277-42-1

Tacrolimus CAS: 104987-11-3

Trilostane CAS: 13647-35-3

Rapamycin CAS: 53123-88-9

PF-2341066/Crizotinib CAS: 877399-52-5

Everolimus CAS: 159351-69-6

Zoledronic acid CAS: 118072-93-8

Rasagiline mesylate CAS: 161735-79-1

Clopidogrel hydrogen sulfate CAS: 135046-48-9

Doxepin hydrochloride CAS: 1229-29-4

   

   


Send your message to this manufacturer
Email:
Message:
Your message must be between 20-8000 characters
 

© 2015 - 2024, wfdbn.com All rights reserved.